|(1S,3aS,4R,7R,8aR)-1,4-二羟基-4-(羟甲基)-1-甲基-7-((2-(((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)丙-2-基)八氢薁-2(1H)-酮|CsnPharm

CAS No.: 126054-77-1

Atractyloside A/苍术苷 A Catalog No. CSN17638

Synonyms: 苍术苷 A

Atractyloside A is a natural TCM reference compound.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Atractyloside A is a natural TCM reference compound. The atractyloside might be potentially targets CAFs (cancer-associated fibroblasts) and inhibits the development as well as metastasis of CC(colon cancer) by changing the TM E(tumor microenvironment)^[1]. ATR (Atractyloside) treatment blocks ANT2 (Adenine nucleotide translocase 2) expression, promotes the activation of AMPK, then decreases the mTOR activity, and finally promotes autophagosomes formation, thus accelerating the degradation of HFD(high-fat diet)-induced accumulated lipids in the liver^[2]. Treatment with AA increased MTL, GAS, ZO-1, and OCLN levels, while reducing AQP1, AQP3, and FGF2 levels. In addition, phosphorylation of p38 and myosin light-chain kinase (MLCK) expression were inhibited. AA (Atractyloside A) improved gastrointestinal function by protecting the intestinal mucosal barrier via inhibition of the p38 MAPK pathway^[3]. Low concentrations (2.5, 5, and 7.5 μM) of ATR treatment could activate autophagy to accelerate the degradation of TGs in steatosis HepG2 cells; the mechanism may be related to the activation of the AMPK/mTOR pathway induced by the increased ADP/ATP ratio. In addition, the ideal concentration of ATR for improving steatotic HepG2 cells was 7.5 μM^[4].
参考文献

[1] Qi L, Song F, Han Y, Zhang Y, Ding Y. Atractyloside targets cancer-associated fibroblasts and inhibits the metastasis of colon cancer. Ann Transl Med. 2020 Nov;8(21):1443
[2] Zhang P, Cheng X, Sun H, Li Y, Mei W, Zeng C. Atractyloside Protect Mice Against Liver Steatosis by Activation of Autophagy via ANT-AMPK-mTORC1 Signaling Pathway. Front Pharmacol. 2021 Sep 21;12:736655
[3] Tu J, Xie Y, Xu K, Qu L, Lin X, Ke C, Yang D, Cao G, Zhou Z, Liu Y. Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier. Front Pharmacol. 2020 Nov 20;11:583160
[4] Zhang P, Li L, Sun H, Zhang Y, Zhang G, Zhang T, Zeng C. Mitochondrial Energy-Regulating Effect of Atractyloside Inhibits Hepatocellular Steatosis Through the Activation of Autophagy. Front Pharmacol. 2020 Sep 30;11:575695

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2296 mL
- 11.1482 mL
- 22.2963 mL
- 5 mM
- 0.4459 mL
- 2.2296 mL
- 4.4593 mL
- 10 mM
- 0.2230 mL
- 1.1148 mL
- 2.2296 mL

技术信息

CAS号

126054-77-1

储存条件

粉末: Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C21H36O10

运输

蓝冰

分子量

448.50

别名

苍术苷 A

溶解度

DMSO	20.0 mg/mL (44.6 mM)

动物实验配方

5% DMSO + 30% PEG400 +2% tween80 + 63% water

1 mg/mL

clear

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Atractyloside A/苍术苷 A Catalog No. CSN17638

靶点选择性

请登录您的专属账户

确认信息